NASDAQ · Biotechnology
CLNN (CLNN) Stock
$4.24
-0.93%
NASDAQ: CLNN
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Top Premarket Decliners
MT Newswires · Jun 22, 2026
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
Zacks · Jun 18, 2026
Clene (CLNN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Zacks · Jun 4, 2026
3 Parkinson's Biotech Stocks Analysts Think Are Wildly Mispriced
Simply Wall St. · May 22, 2026
Are Medical Stocks Lagging BrightSpring Health Services, Inc. (BTSG) This Year?
Zacks · May 19, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held17.06%
Institutions Held20.44%
Institutions Float Held24.64%
Peer Comparison
About CLNN
CLNN is led by CEO Robert Etherington, employs 75 people, headquartered in US, publicly traded since 2018.
CLNN stock trades at $4.24 with a market capitalization of $54.18M. The stock is valued at a price-to-earnings (P/E) ratio of -1.31, price-to-book of -2.32, price-to-sales of 301.62. Over the past 52 weeks the stock has ranged between $3.88 and $13.50, and currently trades 68.6% below its 52-week high.
On profitability, CLNN generates a return on equity (ROE) of 214.97% — well above the market average, a sign of a high-quality business, return on capital employed of -111.61%, an operating margin of 0.00%, a net profit margin of -250.10%.